

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739

Status	RECRUITING
Phase	Phase 2
Sponsor	Abcentra
Enrollment	240 participants

Key Eligibility Criteria

Inclusion (13)

- Participant must provide informed consent before any study specific activities are performed, must be able and willing to meet all requirements for randomization and must adhere to the schedules of activities.
 - Participant must be \geq 180 days after presumed type-1 myocardial infarction (i.e., due to plaque rupture or erosion, either STEMI or NSTEMI) without subsequent unstable or severe angina (Canadian Cardiovascular Society Class 3 or 4) at the time of enrollment. Participants who have undergone PCI are allowed.
 - Participant must be on a stable cardiovascular treatment regimen consistent with local treatment guidelines for post-AMI patients (such as maximally tolerated statin and/or PCSK9 inhibitor medication for LDL reduction, antiplatelet medication, and hypertension treatment).
 - Participant must have an evaluable, pre-randomization CCTA with one of the following:
 - A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 50th centile (per reference standard) for their age group in at least two coronary arteries or
- ... and 8 more (see full listing online)

Exclusion (40)

- History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
 - Percutaneous coronary intervention or invasive diagnostic coronary angiogram planned after screening. Eligible participants who have an invasive diagnostic coronary angiogram performed in the absence of undergoing a new PCI may continue screening after the diagnostic angiogram has been performed or may be rescreened.
 - History of or planned coronary artery bypass grafting.
 - Documented episode of post-MI pericarditis in the 3 months before enrollment.
 - Presence of unstable or uncontrolled angina. Canadian CV society (CCS) angina class \geq 2.
- ... and 35 more (see full listing online)

Locations (41 total)

Abcentra Investigational Site, Los Angeles, California, United States
Abcentra Investigational Site, Torrance, California, United States
Abcentra Investigational Site, Boca Raton, Florida, United States
... and 38 more locations

<https://clinicaltrials.gov/study/NCT06927739>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.